Bristol-Myers Squibb share price today

Bristol-Myers Squibb Company's share price was $64.20 at the close on 4 November 2026. It has been rising for 4 weeks. That is 6.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between $46 and $67, and at that close it sat 86% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Bristol-Myers Squibb Company is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 5 weeks running.

Over the last 10 years the share price moved −15% while the S&P 500 moved +261%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 2 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Bristol-Myers Squibb Company paid $2.52 per share over the last four reported quarters. The most recent declaration was $0.63 for Sep 2026. At today's price of $64.20 that is a yield of 3.93%, based on dividends already paid, not a forecast.

A dividend is cash paid out for each share. The 12-month total is the four most recent quarters added together.

Bristol-Myers Squibb is on one of our US lists: S&P 500 companies.

Bristol-Myers Squibb Company earned $2.2 B of net profit in the Sep 2026 quarter, −1.8% on the same quarter a year earlier. Full-year FY25 profit was $7.1 B. Over 4 years profit has grown 0.2% a year on average. That is 16.5% of the quarter's revenue. The same quarter a year earlier earned $2.2 B.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

1 of the last 12 reported quarters were loss-making.

Why profit moved: revenue changed +6.9% on a year earlier and the margin moved +2.2 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +392.5% and revenue +4.1%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit.

Bristol-Myers Squibb Company reported $13.1 B of revenue in the Sep 2026 quarter, +6.9% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 4 years it has grown 1.0% a year on average. The last full year, FY25, came in at $48.2 B.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $50.0 B.

FY25 revenue was $48.2 B, −0.2% on the year before.

Recent pace: the last four quarters grew +4.1% on average, against 1.0% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +4.2%, against +2.7% a year over the last 8 quarters (stabilising).

Bristol-Myers Squibb Company's operating margin was 33.8% in the Sep 2026 quarter, 2.2 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 18.5% and 31.2%. The latest quarter is above every full year in that period.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Across 5 years it has been between 18.5% and 31.2%, and FY25's 31.2% is the highest of them.

Why the margin moved: operating margin changed +2.2 percentage points on the year while gross margin changed −4.5 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

Over the last 3 years, 192% of Bristol-Myers Squibb Company's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $14.2 B of operating cash against $7.1 B of profit. After $1.3 B of spending on assets, $12.8 B was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Bristol-Myers Squibb Company does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $3.8 B on assets over the last 3 years. Averaged over those years that is 2.6% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $3.8 B over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Bristol-Myers Squibb Company's P/E is 14.2×, near the low end of its own history: it has been lower only 26% of the time. Its usual P/E (the middle reading) is 17.0×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.